# Celgene (CELG)

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” there is no complicated scientific and clinical information, leaving the details to the articles that we usually...

Prohost Biotech

Nov 12, 2019

What A Week For Biotechnology

Prohost Biotech

Nov 11, 2019

7

Amgen Agreement with Celgene for Otezla® In the News Amgen (AMGN) entered into an agreement with Celgene (CELG) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatme...

Amgen to Acquire Celgene's Product Otezla at $13.4 Billion

Gilead Sciences Activities There is no doubt that Gilead Sciences ( GILD ) is doing whatever it takes to expand, improve and upgrade its pipeline products. For the last couple of months, each and e...

Prohost Biotech

Aug 26, 2019

Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

Prohost Biotech

Jul 22, 2019

4

A Great Day for Bluebird bio and Celgene Read the Clinical Trial Results for Myeloma What a Great Day! Jobs reaching the moon. Inflation not yet showing any concerning signs. A fiercely rebounding st...

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last Resort Multiple Myeloma Treatment

Bristol-Myers Squibb (BMY) will acquire Celgene (CELG) i n a cash and stock transaction with an equity value of approximately $74 billion . Under the terms of the agreement: Celgene shareholders wi...

Prohost Biotech

May 3, 2019

Bristol-Myers to acquire Celgene. Was this move really a surprise?

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, the Prime Minister of England, delayed the Brexit vote! The question becomes, what will be put forth next as a...

Prohost Biotech

Jan 3, 2019

Politics and the Market

Today, the market took another beating as a result of either an intentional or an unintentional lack of clearance by professionals in describing correctly the standing of employment and other current...

Prohost Biotech

Dec 11, 2018

There are no reasons for the Market's tumbling. The value of the Biotech Revolution.

Prohost Biotech

Dec 7, 2018

0

At the 60th American Society of Hematology (ASH) Annual Meeting CAR T is Still a Star With all the pessimistic views critics have sprayed around in the past few years about the cell therapy for can...

Celgene has important CAR T presentations at ASH

The Week in Review #23 ASCO 2018 - Small publicly-traded oncology biotech firms, large oncology biotech firms, and giant biopharmaceutical firms, in addition to some private biot...

Prohost Biotech

Dec 4, 2018

Good News, Bad News & Comebacks. See Also: ASCO Results

IN THE NEWS PTC THERAPEUTICS PTC Therapeutics (PTCT) stock, which dipped yesterday, probably on news announcing a public offering of 4,000,000 shares of its common stock at a public offering price...

Prohost Biotech

Jun 19, 2018

News from PTC Therapeutics, Celgene and Heron Therapeutics

Prohost Biotech

Mar 29, 2018

1

Celgene (CELG) and Juno (JUNO) announced the signing of a definitive merger agreement upon which Celgene has agreed to acquire Juno. Celgene will pay $87 per share in cash, or a total of approximately...

Celgene Acquires Juno Therapeutics at $9 Billion or $87 a Share. Why Array is Trading Around $15 in Premarket Today.

Prohost Biotech

Jan 22, 2018

5m

3

Juno Therapeutics’ (JUNO) stock price orbited the moon after-hours trading yesterday, rising 45%, following a wall street journal report stating that Celgene (CELG) was in discussions to take over Jun...

Juno Therapeutics’ Stock Rally. Exelixis’ Successful Trial for Liver Cancer

Juno Therapeutics (JUNO) is one of the casualties that occurred during the 59 th American Society of Hematology (ASH) Annual Meeting. The stock experienced undeserved selloff except for the fact tha...

Prohost Biotech

Jan 17, 2018

Juno and Spark: On the Road Towards Ambitious Goals

Prohost Letter #414 GIANTS & DWARFS - We believe it’s a useful idea bringing The Week in Review into the Prohost Letter this time. We thought it would be easier for the readers to get last week’s upda...

Prohost Biotech

Dec 12, 2017

Prohost Letter #414

Coming Soon... The Week in Review #3 Gilead Acquisition - Rallying by Association - Improving on Cancer Treatments... ...

Prohost Biotech

Oct 25, 2017

Gilead's Acquisition Effect on Other CAR-T Developers' Stocks

Prohost Biotech

Sep 4, 2017

7

CELGENE Good news from Celgene (CELG) announced that the FDA approved the firm’s targeted drug Idhifa (enasidenib) for adults with relapsed or refractory acute myeloid leukemia (AML) associated with...

An Approval for Celgene and Two Breakthrough Designations for AstraZeneca

As we wrote yesterday, immunotherapy checkpoint inhibitors represent a great advancement and big changes in the management of cancer. It is pertinent, though, to keep in mind that these immuno-oncolog...

Prohost Biotech

Aug 2, 2017

Celgene and Immunotherapy: An Unfolding Story

Prohost Biotech

Jul 8, 2017

5

Merck’s (MRK) anti-PD-1 drug Keytruda® (pembrolizumab) is approved for many, many cancers. Yet, it is fair to say that this checkpoint inhibitor drug will not be effective in all cancers. This is espe...

Merck's Keytruda: Extremely Valuable, But Not for Multiple Myeloma

Prohost Biotech

Jul 6, 2017

7m

1

EPIZYME Many oncologists, we believe, must be impatient to learn about the outcome of a first-in-class cancer drug based on epigenetics in upcoming oncology conventions. The drug tazemetostat was crea...

Why Epizyme's Upcoming Presentation Is More Than Exciting